1-6 of 6
Eva Ciruelos
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study

Patrick Neven, Nicole Stahl, Maria Vidal, Miguel Martín, Peter A. Kaufman, Nadia Harbeck, Kelly K. Hunt, Stacey Carter, Francois-Clement Bidard, Peter A. Fasching, Philippe Aftimos, Duncan Wheatley, Erika Hamilton, Rebecca Aft, Swati Kulkarni, Peter Schmid, Manali Bhave, Roohi Ismail-Khan, Claudia Karacsonyi, Shawn T. Estrem, Bastien Nguyen, Umut Ozbek, Eunice Yuen, Vanessa Rodrik-Outmezguine, Eva Ciruelos
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (23): 5304–5313.
https://doi.org/10.1158/1078-0432.CCR-24-2113
Published: 02 December 2024
View article titled, A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study
Open the PDF for A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study in another window
Includes: Supplementary data
Journal Articles

A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor–positive HER2-negative Breast Cancer

Aleix Prat, Yi-Hsuan Tsai, Tomás Pascual, Laia Paré, Barbara Adamo, Maria Vidal, Fara Brasó-Maristany, Patricia Galván, Jan Christoph Brase, Vanessa Rodrik-Outmezguine, Stephen Johnston, Eva Ciruelos, Joel S. Parker
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (23): 6141–6148.
https://doi.org/10.1158/1078-0432.CCR-20-2793
Published: 01 December 2020
View article titled, A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor–positive HER2-negative Breast Cancer
Open the PDF for A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor–positive HER2-negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial

Eva Ciruelos, Patricia Villagrasa, Tomás Pascual, Mafalda Oliveira, Sonia Pernas, Laia Paré, Santiago Escrivá-de-Romaní, Luis Manso, Barbara Adamo, Eduardo Martínez, Javier Cortés, Silvia Vazquez, Antonia Perelló, Isabel Garau, Mireia Melé, Noelia Martínez, Alvaro Montaño, Begoña Bermejo, Serafin Morales, María J. Echarri, Estela Vega, Blanca González-Farré, Débora Martínez, Patricia Galván, Jordi Canes, Paolo Nuciforo, Xavier Gonzalez, Aleix Prat
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (22): 5820–5829.
https://doi.org/10.1158/1078-0432.CCR-20-0844
Published: 13 November 2020
View article titled, Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial
Open the PDF for Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial in another window
Includes: Supplementary data
Journal Articles

Abstract PO-020: Impact of CDK 4/6i withdrawal or dose adjustment on COVID-19 incidence in HR+/HER2- mBC patients during the pandemic

Pablo Tolosa, Ana Sanchez-Torre, Helena Bote de Cabo, Rodrigo Sánchez-Bayona, Mercedes Herrera, Ramón Yarza, Laura Lema, Luis Manso, Eva Ciruelos
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (18_Supplement): PO-020.
https://doi.org/10.1158/1557-3265.COVID-19-PO-020
Published: 15 September 2020
View article titled, Abstract PO-020: Impact of CDK 4/6i withdrawal or dose adjustment on COVID-19 incidence in HR+/HER2- mBC patients during the pandemic
Journal Articles

Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer

Nancy U. Lin, Véronique Diéras, Devchand Paul, Dominique Lossignol, Christos Christodoulou, Hans-Joachim Stemmler, Henri Roché, Minetta C. Liu, Richard Greil, Eva Ciruelos, Sibylle Loibl, Stefania Gori, Andrew Wardley, Denise Yardley, Adam Brufsky, Joanne L. Blum, Stephen D. Rubin, Bernie Dharan, Klaudia Steplewski, Denise Zembryki, Cristina Oliva, Debasish Roychowdhury, Paolo Paoletti, Eric P. Winer
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (4): 1452–1459.
https://doi.org/10.1158/1078-0432.CCR-08-1080
Published: 19 February 2009
View article titled, Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer
Open the PDF for Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I Clinical and Pharmacokinetic Study of Kahalalide F Administered Weekly as a 1-Hour Infusion to Patients with Advanced Solid Tumors

Beatriz Pardo, Luis Paz-Ares, Josep Tabernero, Eva Ciruelos, Margarita García, Ramón Salazar, Ana López, María Blanco, Antonio Nieto, José Jimeno, Miguel Ángel Izquierdo, José Manuel Trigo
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (4): 1116–1123.
https://doi.org/10.1158/1078-0432.CCR-07-4366
Published: 15 February 2008
View article titled, Phase I Clinical and Pharmacokinetic Study of Kahalalide F Administered Weekly as a 1-Hour Infusion to Patients with Advanced Solid Tumors
Open the PDF for Phase I Clinical and Pharmacokinetic Study of Kahalalide F Administered Weekly as a 1-Hour Infusion to Patients with Advanced Solid Tumors in another window